Last reviewed · How we verify

treatment and prophylaxis of hypokalemia with or without metabolic alkalosis — Treatment Landscape & Competitive Intelligence

treatment and prophylaxis of hypokalemia with or without metabolic alkalosis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Potassium Chloride POTASSIUM Nesher Pharms 2025-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Nesher Pharms · 1 drug in treatment and prophylaxis of hypokalemia with or without metabolic alkalosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in treatment and prophylaxis of hypokalemia with or without metabolic alkalosis:

Cite this brief

Drug Landscape (2026). treatment and prophylaxis of hypokalemia with or without metabolic alkalosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-and-prophylaxis-of-hypokalemia-with-or-without-metabolic-alkalosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing